Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer [Yahoo! Finance]
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer
Delcath Systems Stock (NASDAQ:DCTH) Among the Best Multibagger Stock to Buy Heading into 2025 [Yahoo! Finance]
Delcath Systems, Inc. (NASDAQ: DCTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]